TABLE 1

Predictor Variables and Response for Each Patient

Patient no.*	Total tumor burden^†	LDH level^‡	Hybrid SPECT^§			Conjugate views			Response^¶
Patient no.*	Total tumor burden^†	LDH level^‡				No. of individual tumors	Average dose (cGy)	No. of composite tumors	Response^¶	Average dose (cGy)
1	L	N	5	1,469	2	646	CR
2	S	N	2	209	1	2,638	CR
3	L	N	11	219	3	782	PR
5	L	E	1	213	1	713	CR
7	L	E	4	281	1	431	PR
9	L	N	3	267	2	658	CR
10	L	N	2	545	1	936	CR
11	L	E	1	570	1	222	PR
12	L	N	2	1,093	1	1,161	CR
13	S	N	2	1,339	1	740	CR
14	L	N	2	735	1	635	CR
15	L	E	1	294	1	635	CR
16	S	E	4	817	1	1,032	CR
24	S	E	2	2,544	1	1,782	CR
26	L	N	1	672	1	409	CR
27	L	N	5	740	1	1,034	CR
30	S	N	2	651	1	529	PR
31	L	N	5	933	1	490	PR
32	S	N	3	400	1	815	CR
33	L	E	2	385	1	422	CR
34	L	N	3	526	1	1,924	PR
36	S	E	10	573	3	2,521	CR
37	S	N	5	579	2	888	CR
39	S	N	6	789	1	1,849	CR
40	S	N	1	837	1	7,659	CR
42	L	N	3	876	1	331	CR
43	S	N	9	352	1	2,765	PR
44	S	N	4	578	2	719	CR
45	S	N	4	523	1	3,517	PR
46	S	N	9	545	3	1,238	CR
47	S	E	1	471	1	4,674	CR
48	L	E	5	357	2	620	PR
49	L	E	4	1,333	1	772	CR
53	S	E	1	300	1	510	CR
55	S	N	5	558	2	2,071	CR
56	S	N	7	389	3	2,670	CR
59	L	N	8	428	3	874	CR
60	S	E	1	321	1	1,769	CR
62	L	E	2	190	2	423	CR
64	S	NA	7	812	1	1,126	CR
66	S	N	2	562	1	940	CR
67	S	N	2	431	1	361	CR
69	S	N	3	978	1	2,747	CR
70	L	N	6	175	2	727	CR
71	S	N	5	363	2	1,410	CR
73	L	N	5	987	1	871	CR
76	S	E	2	125	1	669	CR

↵* Patient’s identification number.
↵^† L is large (>500 g) and S is small (<500 g).
↵^‡ N is normal or low, E is elevated, and NA is not available.
↵^§ Dose estimation by hybrid pretherapy conjugate-view intratherapy SPECT method.
↵^¶ Patient’s response to therapy: either CR or PR.